Boston Scientific (BSX) said Friday that it completed the acquisition of Axonics (AXNX), a medical technology company specializing in devices for urinary and bowel dysfunction.
The company said the deal, which has an equity value of $3.7 billion and an enterprise value of $3.3 billion, is expected to be immaterial to adjusted earnings per share in 2024 and 2025 and become accretive afterward.
Boston Scientific also said that the deal is slated to be less accretive on a GAAP basis due to amortization and acquisition-related costs.
Price: 87.12, Change: -0.47, Percent Change: -0.54
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.